Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.
Read More
When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.
Read More
Sleepwalking is a rare side effect on psychiatric medications, particularly hypnotics and antidepressants. A new analysis explores whether lithium and the antipsychotics should be added to that list.
Read More
In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.
Read More
Gordon Parker takes on the DSM and offers up a practical approach to diagnosing bipolar disorder. Included is a new self-rated scale that Dr. Parker developed to separate normal good moods from hypomania.
Read More
Nutritional psychiatry has come of age with three randomized controlled trials supporting its role in depression. Drew Ramsey, MD, explains how to blend these techniques in with old-school treatments.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
